Relationship between Oxidative Stress, Inflammation and Dyslipidemia with Fatty Liver Index in Patients with Type 2 Diabetes Mellitus by Klisić, Aleksandra et al.
Klisic A et al. Relationship between Oxidative Stress,. Exp Clin Endocrinol Diabetes 2018; 126: 371–378
Article Thieme
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the commonest form 
of chronic liver diseases [1] and is tightly associated with insulin re-
sistance [2, 3]. Therefore, the high prevalence of this metabolic dis-
order observed in individuals with obesity or type 2 diabetes mel-
litus (DM2), [4] is not suprising. It is estimated that more than 
60–70 % of DM2 patients are affected by NAFLD [4, 5].
There is also evidence of association between NAFLD and long-
term diabetes complications such as diabetic retinopathy and 
chronic kidney disease [6].
Relationship between Oxidative Stress, Inflammation and 
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Introduction/Aim Considering the high prevalence of non-
alcoholic fatty liver disease (NAFLD) in individuals with type 2 
diabetes mellitus (DM2), we aimed to investigate the potential 
benefit of determining markers of oxidative stress, inflamma-
tion and dyslipidemia for prediction of NAFLD, as estimated 
with fatty liver index (FLI) in individuals with DM2.
Methods A total of 139 individuals with DM2 (of them 49.9 % 
females) were enrolled in cross-sectional study. Anthropomet-
ric and biochemical parameters, as well as blood pressure were 
obtained. A FLI was calculated.
Results Multivariate logistic regression analysis showed that 
high density lipoprotein cholesterol (HDL-c) and malondialde-
hyde (MDA) were independent predictors of higher FLI [Odds 
ratio (OR) = 0.056, p = 0.029; and OR = 1.105, p = 0.016, respec-
tively]. In Receiver Operating Characteristic curve analysis, the 
addition of fatty liver risk factors (e. g., age, gender, body 
height, smoking status, diabetes duration and drugs metabo-
lized in liver) to each analysed biochemical parameter [HDL-c, 
non-HDL-c, high sensitivity C-reactive protein (hsCRP), MDA 
and advanced oxidant protein products (AOPP)] in Model 1, 
increased the ability to discriminate patients with and without 
fatty liver [Area under the curve (AUC) = 0.832, AUC = 0.808, 
AUC = 0.798, AUC = 0.824 and AUC = 0.743, respectively]. 
Model 2 (which included all five examined predictors, e. g., 
HDL-c, non-HDL-c, hsCRP, MDA, AOPP, and fatty liver risk fac-
tors) improved discriminative abilities for fatty liver status 
(AUC = 0.909). Even more, Model 2 had the highest sensitivity 
and specificity (89.3 % and 87.5 %, respectively) together than 
each predictor in Model 1.
Conclusion Multimarker approach, including biomarkers of 
oxidative stress, dyslipidemia and inflammation, could be of 
benefit in identifying patients with diabetes being at high risk 
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In addition, diabetic individuals with NAFLD have 2 fold increase 
risk for development and progression of cardiovascular disease [7], 
and also 2 to 3 fold higher risk of dying of chronic liver disease [8], 
compared to diabetic individuals without NAFLD.
The pathophysiological mechanism underlying NAFLD is not 
well elucidated. However, it is speculated that oxidative stress and 
inflammation are the key determinants of this hepatic manifesta-






insulin signalling pathways, thus leading to consequent insulin re-
sistant state, increased free fatty acids hepatic influx, increased 
lipogenesis, as well as triglyceride storage, inducing hepatocytes 
dysfunction or death [18].
To our knowledge, there are no data examining the oxidative 
stress markers in relation to NAFLD in exclusively patients with 
DM2. Furthermore, considering the high prevalence of NAFLD in 










This cross-sectional study derived from a previous work aiming to 
evaluate the utility of visceral adiposity indexes in individuals with 
DM2 [19].
The study enrolled a total of 139 sedentary DM2 (of them 49.9 % 
females) who volunteered to participate in the study. All examined 
patients were recruited by the endocrinologist in the Center of Lab-
oratory Diagnostics of the Primary Health Care Center in Podgori-
ca, Montenegro, for their regular biochemical analyses check-up 
in a period from October 2015 to May 2016. Medical history and 
clinical examinations were carried out on the same day.
Out of the total number of 362 patients with diabetes (207 men 
and 155 women), who were screened for the study, 139 of them 
met the criteria for inclusion in the study (71 men and 68 women).
The methods and assays used to include participants and to ex-
clude disorders in participants with diabetes have been described 
in detail elsewhere [19].











matory disease, high sensitivity C-reactive protein levels 
(hsCRP)  > 10 mg/L, pregnancy, history or the presence of malignan-
cy, as well as participants who were unwilling to enter the study [19].







gible to enter the study were divided into two groups (FLI < 30, 
n = 17; and FLI ≥ 60; n = 122).
A total of 87.1 % of participants used oral antihyperglycemics 
[of them metformin, sulfonylureas, inhibitors of dipeptidyl pepti-
dase 4 (DPP-4 inhibitors) were used by 81.8 %, 5.8 %, and 17.1 % pa-
tients, respectively], whereas 16.5 % of them were on insulin ther-
apy. All participants who used lipid-modifying drugs (46.8 %) in our 
study used statins (100 % of them), whereas the smaller number of 
them used fibrates, also (4.6 %). Antihypertensive medication usage 
was recorded in 73.4 % participants [of them angiotensin convert-
ing enzyme inhibitors (ACE inhibitors), beta-blockers, and diuret-
ics were used by 87.3 %, 20.6 % and 52.9 % patients, respectively].
All the participants provided written informed consent. The 
study protocol was approved by the Ethical Committee of Primary 
Health Care Center in Podgorica, Montenegro and the research was 
carried out in compliance with the Declaration of Helsinki.
Anthropometric measurements
Basic anthropometric measurements: body height (cm), body 
weight (kg) and waist circumference (WC) (cm) were obtained, and 
body mass index (BMI) was calculated, as described previously 
[2, 19]. Waist-to-height ratio (WHtR) was calculated as waist (cm) 
divided by height (cm).
Biochemical analyses
Biochemical parameters were measured as previously described 
[19]. The blood samples were taken between 7–9 h a.m., after 
12–14 h of an overnight fast. Samples were left to clot for 30 min 
and then centrifuged at 3000 rpm for 10 min.
Glucose levels were determined immediately after the blood 
was drawn, whereas serum samples used for other analyses were 
divided into aliquots and stored at  − 80 °C before analyses. A whole 
blood in K2EDTA was used for determination of HbA1c, and it was 
measured with immunoturbidimetric assay (Roche Cobas 400, 
Mannheim, Germany).
Serum levels of glucose, total cholesterol (TC), high density li-
poprotein cholesterol (HDL-c), low density lipoprotein cholesterol 
(LDL-c), triglycerides (TG), uric acid, bilirubin, aspartat aminotrans-
ferase (AST), alanine aminotransferase (ALT) and gamma-glutamil 
transferase (GGT), were measured as described previously [19], 
using standardized enzymatic procedure (Roche Cobas 400, Man-
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els were determined using a nephelometric assay (Behring Neph-
elometer Analyzer, Marburg, Germany).
Determination of serum AOPP was based on spectrophotomet-
ric detection of chloramine-T equivalents. In order to minimize the 
impact of storage time of samples as well as the possible influence 
of triglycerides and turbidity of samples, we modified AOPP assay 
by precipitating VLDL and LDL in the plasma. It was reported in a 
number of clinical disease states and method was developed in our 
previous reports [22].
Serum MDA levels were measured spectophotometrically. The 
MDA determination by measuring TBARS by thiobarbituric acid 
(TBA) test is described as the most-commonly employed approach. 
It was reported as a true measure of MDA in a number of clinical 
disease states and in our previous reports [23].
Catalase (CAT) test is based on the release of oxygen from hydro-
gen peroxide (H2O2), by using the spectrophotometric assay based 
on formation of its stable complex with ammonium molybdate. Cat-
alase activity determination was reported in a number of clinical 




Disease Study equation (eGFRMDRD) as described previously [19].
Statistical analysis
Data were presented as median (interquartile range) and compared 
by Mann–Whitney U-test. Comparison of categorical data given as 
absolute frequencies was performed with Chi-square test. Spear-
man’s correlation analysis was used to estimate the correlation be-
tween clinical parameters and FLI. Logistic regression analysis with 
enter selection principle was used to analyze determination of one 
or more independent or predictor variables (demographic charac-
teristics, inflammation, lipid and oxidative stress markers) on the 
occurrence of fatty liver (dichotomous dependent variable). Also, 
it was used to identify independent determinants of FLI. Linear re-




ent variable was presented by Nagelkerke R Squared (pseudo R2) 
value. The diagnostic potential of predictors was evaluated using 
Receiver Operating Characteristic (ROC) curve analysis. The area 
under ROC curve (AUC) was used as a measure how well predictors 
could distinguish between subjects that suffered from fatty liver 
from those who did not. All statistical calculations were performed 




The general characteristics of patients with DM2 divided accord-
ing to the FLI values are indicated in ▶table 1. As expected, there 
were significant differences between groups in all parameters (ex-
cept for height) which were used in FLI calculation. Body weight, 
BMI, WC, WHtR were statistically higher in the group with FLI  ≥ 60 
than in the group with FLI  < 30 (p < 0.001 for all). Also, patients in 
the group with FLI  ≥ 60 had significantly higher SBP than those in 
the group with FLI  < 30 (p = 0.027). Duration of diabetes of patients 
in the group with FLI  ≥ 60 was significantly shorter than in the group 
with FLI  < 30 (p = 0.010). There were unequal distributions of pa-
tients with smoking habits, hypolipemic and antihyperglycemic 
therapies usages according to Chi-square test (▶table 1).
A significantly lower HDL-c concentration (p = 0.003) was found 
in the group with FLI  ≥ 60 than in the group with FLI  < 30 (▶table 2). 





cantly higher levels of glucose, hsCRP, uric acid, MDA and AOPP 
(p = 0.038, p = 0.002, p = 0.033, p = 0.001 and p = 0.005, respective-
ly) in the group with FLI  ≥ 60 comparing with the group with 
FLI  < 30 (▶table 2).
Spearman’s correlation analysis was used to test possible asso-
ciations between FLI and examined clinical parameters in the co-
hort of patients with DM2 (▶table 3). We found a significant neg-
ative correlation between FLI and HDL-c (p < 0.001), FLI and years 
of age (p = 0.001) and FLI and diabetes duration (p = 0.013). Posi-
tive correlations were evident between FLI and concentrations of 
glucose, HBA1c, hsCRP, MDA and AOPP (p = 0.001, p = 0.009, 
p < 0.001, p = 0.015 and p = 0.019, respectively).
Multivariate logistic regression analysis was used to further in-
vestigate the associations of clinical parameters which were signif-
icantly different between the group with FLI  ≥ 60, and the group 
with FLI  < 30, with fatty liver development, unadjusted and after 
adjustment for other risk factors (▶table 4). Unadjusted ORs 
showed that HDL-c, non-HDL-c, hsCRP, uric acid, MDA and AOPP 
had significant potential for fatty liver risk prediction. Also, unad-
justed regression models correctly classified around 88 % of pa-
tients in the group having fatty liver. Model 1 presented adjustment 
for fatty liver risk factors (e. g., age, gender, body height, smoking 
status, diabetes duration and drugs metabolized in liver) with HDL-
c, non-HDL-c, hsCRP, MDA and AOPP respectively, and revealed that 
HDL-c, non-HDL-c, hsCRP and MDA were the independent risk pre-
dictors for fatty liver occurrence. As HDL-c concentration fall for 
1 mmol/L, probability for higher fatty liver occurrence risk rose for 
97.6 % (OR = 0.024, p = 0.001). As non-HDL-c rose for 1 mmol/L, 
probability for fatty liver occurence rose almost 3 times (OR = 2.725, 
p = 0.006). With increment in hsCRP concentration for 1 mg/L, 
probability for higher fatty liver occurrence risk rose for 37.9 % 
(OR = 1.379, p = 0.043). Furthermore, with increment in MDA con-
centration for 1 μmol/L, probability for higher fatty liver occurrence 
risk rose for 12.0 % (OR = 1.120, p = 0.001), (▶table 4).
In Model 2, the adjustment was performed for fatty liver risk fac-
tors (e. g., age, gender, body height, smoking status, diabetes du-
ration, drugs metabolized in liver), together with HDL-c, non-HDL-
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▶table 1  Demographic characteristics of patients with diabetes according to FLI.
FLI  < 30 N = 17 (12.2 %) FLI  ≥ 60 N = 122 (87.8 %) p
N (males/females) 17 (9/8) 122 (62/60) 0.683
Age, years 63 (53–70) 63 (55–69) 0.788
Body weight, kg 72 (69–79) 93 (84–100)  < 0.001
Body height, cm 173 (168–177) 172 (165–179) 0.641
BMI, kg/m2 25.2 (23.3–25.9) 31.1 (28.7–34.1)  < 0.001
WC, cm 90 (86–92) 110 (104–117)  < 0.001
WHtR 0.51 (0.50–0.54) 0.64 (0.60–0.69)  < 0.001
SBP, mmHg 129 (136–144) 135 (126–144) 0.028
DBP, mmHg 70 (66–82) 80 (74–85) 0.064
Smoking habits, (Smokers/Non-smokers) 4/13 28/94 0.011
Antihyperglycemics (Yes/No)
-Metformin (N = 99)
-Sulfonylurea (N = 7)
-DPP-4 inhibitors (N = 22)
15/2 106/16 0.028
Insulin (Yes/No) 5/12 18/104 0.11
Hypolipemics (Yes/No)
-Statins (N = 65)
-Fibrates (N = 3)
9/8 56/66 0.009
Antihypertensives (Yes/No)
-ACE inhibitors (N = 89)
-Beta blockers (N = 21)
-Diuretics (N = 54)
9/8 93/29 0.119
Duration of diabetes, years 7.0 (3.5–10.0) 3.50 (1.0–7.0) 0.01
Data are presented as median (interquartile range) and compared by Mann-Whitney test
Categorical data are presented as absolute frequencies and compared by Chi squared test
▶table 2  Clinical parameters in patients with diabetes according to FLI.
FLI  < 30 N = 17 (12.2 %) FLI  ≥ 60 N = 122 (87.8 %) p
TC, mmol/L 4.79 (4.19–5.78) 5.25 (4.57–6.02) 0.135
HDL-c, mmol/L 1.54 (1.01–1.63) 1.10 (0.88–1.32) 0.003
LDL-c, mmol/L 3.15 (2.34–3.50) 3.07 (2.49–3.89) 0.528
TG, mmol/L 1.12 (0.86–1.43) 2.22 (1.68–3.17)  < 0.001
TG/HDL-c ratio 0.86 (0.59–1.04) 2.11 (1.28–2.98)  < 0.001
Non-HDL-c 3.66 (2.75–4.21) 4.08 (3.48–5.09) 0.025
Glucose, mmol/L 6.50 (5.65–8.55) 7.45 (6.50–9.10) 0.038
HBA1c,  % 5.85 (5.55–7.90) 6.75 (6.00–8.00) 0.148
AST, U/L 17 (14–18) 20 (17–24) 0.003
ALT, U/L 16 (14–19) 24 (17–35) 0.001
GGT, U/L 11 (10–19) 24 (17–34)  < 0.001
HsCRP, mg/L 0.73 (0.45–1.85) 1.75 (1.06–5.15) 0.002
Total bilirubin, µmol/L 7.20 (3.85–12.90) 6.00 (4.80–8.30) 0.641
Creatinine, µmol/L 67 (58–83) 73 (63–86) 0.367
Uric acid, µmol/L 259 (204–339) 321 (265–360) 0.033
eGFRMDRD, mL/min/1.73 m² 90 (81–95) 81 (70–101) 0.301
MDA, µmol/L 44.45 (36.47–54.04) 55.19 (47.80–63.31) 0.001
AOPP, T/L 58.66 (50.25–100.36) 81.88 (67.50–121.66) 0.005
CAT, U/L 70.90 (57.08–93.10) 70.59 (32.88–110.80) 0.855
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The aim of our study was to investigate the potential benefit of 
determining clinical parameters which were different between FLI 
groups in order to discriminate patients with DM2 with fatty liver 
disease from those who did not have it. ROC curves were used to 
achieve this (▶table 5). The calculated AUCs for the measurement 
of single clinical parameter (from 0.660 to 0.753) indicated that the 
clinical accuracy of the applied procedures was low. The same mod-
els were used in ROC analysis as in multivariate logistic analysis. The 
addition of fatty liver risk factors in Model 1 beside each clinical pa-
rameter (HDL-c, non-HDL-c, hsCRP, MDA and AOPP) increased the 
ability to discriminate patients with diabetes with and without fatty 
liver (AUC = 0.832, AUC = 0.808, AUC = 0.798, AUC = 0.824 and 
AUC = 0.743, respectively), (▶table 5, ▶Fig. 1). Model 2 improved 
discriminative abilities for fatty liver development. Calculated AUC 
was 0.909, which gave excellent accuracy of the applied procedure 
(▶table 5, ▶Fig. 2). Even more, the applied Model 2 had the high-
est sensitivity and specificity (89.3 % and 87.5 %, respectively) to-
gether than each predictor in Model 1, (▶table 5).
Discussion
In the current study we reported high prevalence of FLI-NAFLD, ac-
counting for 87.8 % of participants with DM2 to have this metabol-
ic disorder. Moreover, we observed an inverse association between 
age and FLI-NAFLD. The inverse association of FLI-NAFLD with age 
in our study differentiate this diabetic complication from estab-
lished vascular complications, typically related to the duration of 
hyperglycemia [5].
Also, participants with FLI  < 30 displayed longer duration of di-
abetes (▶table 1). Our results are in line with Giorda et al. [5] who 
showed in a large study comprising of more than 5,000 participants 
with diabetes, high prevalence of FLI-NAFLD (e. g., 61.3 %) which 
was more frequent among younger male patients or those with a 
shorter duration of diabetes. This unexpected results may be ex-
plained in part by diabetes treatment which may lower intrahepat-
ic lipid content in the group with FLI  < 30, which appear healthier 




tion (as measured with hsCRP), and increased adipokine level such 
as retinol-binding protein 4, as independent predictors of FLI-
NAFLD in a cohort of postmenopausal, otherwise healthy women 
[2]. The current study extends those observations, suggesting that 
oxidative stress has independent influence on fatty liver develop-
ment in patients with DM2.
Mitochondria and the endoplasmic reticulum of hepatocytes via 
the cytochrome P450 enzymes are the primary source of ROS, thus 
further leading to hepatic structural and functional disorders [24].
AOPPs indicates the overall status of the proteins in the cell/tis-
sue, and in the states of increased oxidative stress they are created 
by reactions between plasma proteins and chlorinated oxidants [25].
Previous reports indicate that proteins are equally targeted by 
ROS as the lipids in diabetes [17], showing positive association be-
tween plasma levels of AOPPs and lipid peroxidation products. How-
ever, in the current study, after adjustment for confounding factors 
[4, 5, 26] we revealed that higher MDA, but not AOPP level was the 
independent risk predictor for fatty liver occurrence. This finding 
suggests that MDA is superior to AOPP in fatty liver risk prediction. 
Namely, even though that both MDA and AOPP significantly corre-
lated with FLI-NAFLD in our study (▶table 3), and although higher 
AOPP levels were recorded in the group with FLI  ≥ 60 (▶table 2), 
AOPPs were not retained in multivariate logistic regression analy-
sis as independent predictor of fatty liver occurrence (OR = 1.014, 
p = 0.240; ▶table 4). Nevertheless, in unadjusted model AOPP 
showed significant potential for fatty liver risk prediction.
Malondialdehyde (MDA) is reported to be a primary biomarker 
of lipid peroxidation of poly-unsaturated fatty acids that were at-
tacked by ROS [25, 27] inducing multiple cellular alterations, influ-




damage markers, such as MDA, in individuals with NAFLD [28–30].
On the other hand, no significant difference between groups in 
CAT activity was reported (▶table 2), although previous studies 











zymes, even though they are shown to be progressively depleted 
as metabolic disorder occurs [17].
▶table 3  Associations between FLI and clinical parameters using Spear-
man’s correlation analysis in patients with diabetes.
Variable Rho (ρ) p
Age, years  − 0.277 0.001
Body height, cm  − 0.075 0.385
Diabetes duration, years  − 0.211 0.013
SBP, mm Hg 0.260 0.002
DBP, mm Hg 0.195 0.022
TC, mmol/L 0.048 0.578
HDL-c, mmol/L  − 0.358  < 0.001
LDL-c, mmol/L  − 0.008 0.927
Non-HDL-c, mmol/L 0.114 0.099
Glucose, mmol/L 0.268 0.001
HBA1c,  % 0.222 0.009
HsCRP, mg/L 0.359  < 0.001
Uric acid, µmol/L 0.123 0.151
Creatinine, µmol/L  − 0.072 0.402
eGFRMDRD, mL/min/1.73 m² 0.139 0.105
MDA, µmol/L 0.208 0.015
AOPP, T/L 0.199 0.019
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▶table 4  Estimated odds ratios (OR) after multivariate logistic regression analysis for parameters predicting abilities regarding FLI.
Predictors Unadjusted Or (95 %cI) p Nagelkerke R2  % of cases correctly classified
HDL-c 0.069 (0.012–0.383) 0.002 0.141 87.7
Non-HDL-c 2.115 (1.180–3.791) 0.012 0.109 88.4
HsCRP 1.372 (0.993–1.895) 0.055 0.086 88.4
Glucose 1.291 (0.961–1.736) 0.090 0.058 88.4
Uric acid 1.008 (1.001–1.015) 0.019 0.083 88.4
MDA 1.100 (1.039–1.165) 0.001 0.180 89.1
AOPP 1.023 (1.002–1.045) 0.035 0.077 88.4
Model 1
HDL-c 0.024 (0.003–0.203) 0.001 0.300 89.9
Non-HDL-c 2.725 (1.334–5.565) 0.006 0.261 87.7
HsCRP 1.379 (1.010–1.881) 0.043 0.213 88.4
MDA 1.120 (1.048–1.196) 0.001 0.322 89.9







AOPP 1.014 (0.991–1.039) 0.240
Model 1: adjustment for age, body height, diabetes duration (all continuous variables), gender, smoking habits, therapies (all categorical variables) 
and each predictor
Model 2: adjustment for age, body height, diabetes duration (all continuous variables), gender, smoking habits, therapies (all categorical variables) 
and all predictors
CI-Confidence interval; SE-Standard error
▶table 5  ROC analysis for single parameter and models discriminatory abilities regarding FLI.
Predictors AUc (95 % cI) SE Sensitivity ( %) Specificity ( %) p
HDL-c 0.731 (0.604–0.771) 0.079 86.1 68.7 0.005
Non-HDL-c 0.670 (0.540-0.801) 0.066 31.1 100.0 0.027
HsCRP 0.744 (0.599-0.890) 0.074 80.3 68.7 0.002
Glucose 0.660 (0.507-0.813) 0.078 73.0 56.2 0.038
Uric acid 0.665 (0.515-0.814) 0.076 68.9 62.5 0.033
MDA 0.753 (0.636-0.870) 0.060 84.4 56.2 0.001
AOPP 0.715 (0.632-0.788) 0.085 85.2 56.2 0.012
Model 1
HDL-c 0.832 (0.727-0.937) 0.054 84.4 75  < 0.001
Non-HDL-c 0.808 (0.689-0.927) 0.061 90.2 62.5  < 0.001
HsCRP 0.798 (0.674-0.921) 0.063 75.4 81.2  < 0.001
MDA 0.824 (0.716-0.932) 0.055 86.1 68.7  < 0.001
AOPP 0.743 (0.604-0.882) 0.071 81.1 62.5 0.002
Model 2
HDL-c





Model 1: adjustment for age, body height, diabetes duration (all continuous variables), gender, smoking habits, therapies (all categorical variables) 
and each predictor
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and cytokines, with consequent impairement of insulin action and 
dyslipidemia [12, 17, 18]. Inflammation in the adipose tissue may, 
therefore, precede hepatic inflammation [16]. In addition, second-
ary to insulin resistance, increased cellular uptake of free faty acids 
without any subsequent β-oxidation contributes to the increased 
triglicerides production that, in turn, stimulates secretion of very 
low density lipoprotein (VLDL) in hepatocytes, further contribut-
ing to hepatic steatosis exacerbation [11, 12].
In our study, after adjustment for all fatty liver risk factors 
[4, 5, 26], HDL-c and MDA, still kept significant prediction poten-
tial for fatty liver (▶table 4).
Since the aim of our study was to investigate the potential ben-
efit of determining markers of oxidative stress, inflammation and 
dyslipidemia in order to discriminate patients with DM2 with fatty 
liver disease from those who did not have it, we performed ROC 
analysis. It is important to note that Model 2 (which included con-
founding factors, and all five examined predictors, e. g., HDL-c, 
non-HDL-c, hsCRP, MDA, AOPP) improved discriminative ability for 
fatty liver development (AUC = 0.909). Even more, the applied pro-





DM2 with FLI-NAFLD from those individuals with DM2, but without 
FLI-NAFLD. Also, high sensitivity of the applied procedure (nearly 
90 %) could be used as a good screening procedure in order not to 




Namely, the authors demonstrated that the fold-change of plasma 
triglycerides during a 2 h oral glucose tolerance test and 2 h glucose 
levels, together with the rs738409 C > G single nucleotide polymor-
phism in PNPLA3 may improve the power of the widely used FLI for 
NAFLD prediction.
The main disadvantages of the current study are the small sam-
ple size of our cohort and its cross-sectional design. Moreover, we 
have only calculated the FLI and had no direct measurements of 
hepatic steatosis, such as ultrasound, computed tomography, pro-






a great risk of fatty liver disease. Further studies are needed to con-
firm our results.
Conclusion
Prevention and/or early recognizing of non-alcoholic fatty liver dis-
ease is of urgent need in patients with type 2 diabetes mellitus. In 




tients with high risk of fatty liver disease and its consequences.
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AOPP AUC = 0.743
HsCRP AUC = 0.798
non-HDL-c AUC = 0.808
MDA AUC = 0.824
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▶Fig. 1 ROC curves for Model 1 (with each predictor) discrimina-
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